Ray Trumbo

Ray Trumbo

Ray’s Company

Novartis

Website: http://www.novartis.com

Twitter: @novartis

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a ... More » Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in each of these areas. In 2008, the GroupÂ’s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include cyclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta, in partnership with AstraZeneca which also divested its agrochemical business. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). [ CrunchBase ]

Free Novartis Essay - Automotive

Novartis - “Succession planning had been in effect for a few years,” says Antoine Tirard, the global head of talent management for Novartis. Using an internal assessment process where line managers graded employees, Tirard says, “We had identified high potentials. We knew who we wanted. But ...

Antoine Tirard

Mentioned in this article:
Antoine Tirard

Indian pharma cos hail SC's verdict, say poor will be benefited - daily.bhaskar.com

This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options," Novartis India Ltd Vice- Chairman and Managing Director Ranjit Shahani said. He further added: "Novartis has never been granted an original patent for Glivec in ...

Ranjit Shahani

Mentioned in this article:
Ranjit Shahani

Novartis Exelon Patch now FDA approved to treat patients across all stages of Alzheimer's disease

It exemplifies Novartis' continuing commitment to the Alzheimer's community," said Andre Wyss, President of Novartis Pharmaceuticals Corporation. "With this expanded indication, Exelon Patch can now address a wider range of Alzheimer's patients, including the large population of people ...

Andre Wyss

Mentioned in this article:
Andre Wyss

US sues Novartis in NY again, cites doc kickbacks | khou.com Houston

Novartis - Novartis President Andre Wyss said the company disagreed with the way the government characterized its conduct and stands behind its compliance program. "NPC invests significant time and resources to help ensure we conduct our business in an ethical and responsible manner," Wyss ...

Andre Wyss

Mentioned in this article:
Andre Wyss

Terra Mobile USA - Drug maker Novartis loses India patent battle

Ranjit Shahani, the vice chairman and managing director of Novartis India, said the ruling "will hinder medical progress for diseases without effective treatment options. " He said the court's decision made India an even less attractive country for major investments by international ...

Ranjit Shahani

Mentioned in this article:
Ranjit Shahani

Study Finds Vulnerability in Malaria Parasite

Novartis - ... Stephan Meister UCSD), Lucia Rameh (Boston University, Boston), Joerg Trappe (Novartis Institutes for BioMedical Research, Basel, Switzerland), Dorothea Haasen (Novartis, Basel...

Joerg Trappe

Mentioned in this article:
Joerg Trappe

US sues Novartis in NY again, cites doc kickbacks | News Tribune

Novartis - Novartis President Andre Wyss said the company disagreed with the way the government characterized its conduct and stands behind its compliance program. “NPC invests significant time and resources to help ensure we conduct our business in an ethical and responsible manner,” Wyss ...

Big Pharma waits nervously on Glivec patent verdict - Yahoo! Finance

Ranjit Shahani, vice chairman and managing director of Novartis India Ltd (NOIN.BO), the firm's Indian unit, said cheap generics had an important role to play once drug patents expired, but the company was concerned about the non-recognition of patents that were ultimately needed to ...

Novartis loses patent battle, experts hail court ruling (Roundup)

Novartis India's managing director Ranjit Shahani said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options. " Stating that Novartis will continue to file for patents in India, Shahani said the company will not ...

Join Newsle to find out when Ray Trumbo makes the news.

As a Newsle member, you’ll be able to:

  • Get alerts on Ray Trumbo
  • See news articles & blog posts about Ray Trumbo
  • Follow your friends & colleagues in the news
This profile only includes publicly available information. Questions or comments? Contact Us
Freebase CC-BY
Data from Freebase, licensed under CC-BY
Source: CrunchBase
Data from Wikipedia, licensed under the GFDL